التفاصيل البيبلوغرافية
| العنوان: |
Address for correspondence |
| المؤلفون: |
Refractory Myeloma, Jae Hoon Lee, Seung Tae Lee, Jee Hyun Kim, Sung-soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim, Sung-soo Yoon M. D |
| المساهمون: |
The Pennsylvania State University CiteSeerX Archives |
| المصدر: |
ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/12/6a/J_Korean_Med_Sci_2005_Aug_31_20(4)_598-602.tar.gz |
| سنة النشر: |
2004 |
| المجموعة: |
CiteSeerX |
| مصطلحات موضوعية: |
Key Words, Multiple Myeloma, Drug Therapy, bortezomib, Velcade, Proteasome Endopeptidase Complex, Protease Inhibitors Keun-Wook Lee, Tak Yun |
| الوصف: |
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3 mg/m 2 twice weekly for 2 week in a 3-week cycle). Seven patients were enrolled. The median age of patients was 59 yr. All patients previously received VAD (vincristine, doxorubicin and dexamethasone) and thalidomide chemotherapy. Three patients previously received alkylator-containing chemotherapy and 4 patients, autologous stem cell transplantation. Bortezomib monotherapy resulted in 3 partial remissions (43%), 3 no changes (43%) and 1 progressive disease (14%). One patient who had no response to bortezomib monotherapy experienced partial remission after addition of dexamethasone to bortezomib. The most common serious toxicity was thrombocytopenia (grade 3/4, 10 of 20 cycles (50%)) and grade 3 peripheral neuropathy was developed in 2 of 20 cycles (10%). Drug-related adverse event led to discontinuation of bortezomib in 1 patient. There was no treatment related mortality. Overall |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/zip |
| اللغة: |
English |
| العلاقة: |
http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.355.7043Test |
| حقوق: |
Metadata may be used without restrictions as long as the oai identifier remains attached to it. |
| رقم الانضمام: |
edsbas.438CFD16 |
| قاعدة البيانات: |
BASE |
